The EXPLORE MG Registry for Myasthenia Gravis

NCT03792659 | Recruiting

• 1 other identifier: 1602017284
• Study Type: observational
• Target: 800
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to create a Yale University Department of Neurology Myasthenia Gravis (MG) registry that will be used for current and future research projects involving the study of Myasthenia Gravis.

Conditions

Myasthenia Gravis

Outcome Measures

Primary Outcomes (1)

• The number of successful blood draws will be reported at the conclusion of the sample collection

  Successful Collection of Blood

  8 years

Secondary Outcomes (1)

• The number of stool samples collected will be reported at the conclusion of the sample

  8 years

Study Arms (1)

Neurological Outpatients

Participants in this group will be recruited from the outpatient clinical population at the Yale University Department of Neurology. Treating physicians will make the initial determination of patients' potential eligibility to participate in the study.

Other: Blood Sample Draw

Interventions

Blood Sample Draw OTHER

Approximately 100 cc (less than 1/2 cup) of blood will be drawn from both groups.

Neurological Outpatients

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subjects will be 18 years of age or older with a clinical diagnosis of a Myasthenia Gravis.

You may qualify if:

• Adult patients diagnosed with Myasthenia Gravis presenting to the Yale Department of Neurology for clinical care or research interventions will be invited to donate their biological specimens/clinical data.

Sponsors & Collaborators

• Yale University: lead

Study Sites (1)

Yale-New Haven Hospital

New Haven, Connecticut, 06510, United States

RECRUITING

Related Publications (1)

• Anil R, Kumar A, Alaparthi S, Sharma A, Nye JL, Roy B, O'Connor KC, Nowak RJ. Exploring outcomes and characteristics of myasthenia gravis: Rationale, aims and design of registry - The EXPLORE-MG registry. J Neurol Sci. 2020 Jul 15;414:116830. doi: 10.1016/j.jns.2020.116830. Epub 2020 Apr 16.

  PMID: 32388060 BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

100 cc (less than 1/2 cup) of blood

MeSH Terms

Conditions

Myasthenia Gravis

Condition Hierarchy (Ancestors)

Paraneoplastic Syndromes, Nervous System; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Paraneoplastic Syndromes; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Neurodegenerative Diseases; Neuromuscular Junction Diseases; Neuromuscular Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Richard Nowak, MD, MS

  Assistant Professor, Yale University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Bailey Sheldon, PhD

CONTACT

203-737-7095; bailey.munrosheldon@yale.edu

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Target Duration: 8 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 2, 2019
• First Posted: January 3, 2019
• Study Start: March 30, 2016
• Primary Completion (Estimated): September 30, 2026
• Study Completion (Estimated): October 30, 2026
• Last Updated: November 28, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)